Meropenem Aptapharma (Meropenem Trihydrate)

Meropenem is a carbapenem antibiotic used to treat serious Gram‑negative and Gram‑positive bacterial infections.

• Complicated intra‑abdominal infections: achieves clinical cure and microbiological eradication.
• Complicated urinary tract infections: resolves infection and prevents recurrence.
• Skin and soft tissue infections: provides bacterial clearance and symptom improvement.
• Meningitis: penetrates cerebrospinal fluid to treat bacterial meningitis.
• Sepsis: contributes to rapid bacterial clearance in systemic infection.

• Meropenem binds to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic lysis and bacterial death. The molecule is resistant to many β‑lactamases, giving it a broad spectrum against Gram‑negative, Gram‑positive and anaerobic organisms.

Adverse reactions to meropenem may vary in frequency and severity.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Injection site pain: discomfort at the IV site.
• Rash: mild skin erythema.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Seizures: especially in patients with renal impairment or pre‑existing CNS disorders.
• Clostridioides difficile colitis: severe intestinal infection that can be life‑threatening.

When using meropenem, clinicians should consider several safety measures.

• Renal function: adjust dose in patients with impaired renal clearance.
• Hypersensitivity: avoid in patients with known carbapenem or beta‑lactam allergy.
• Pregnancy: use only if benefit outweighs potential risk; data are limited.
• Concomitant valproic acid: monitor for decreased plasma levels.
• Pediatric use: safety and efficacy not established in children under 3 months.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid)

• Valproic acid: may reduce valproate levels, risking seizure breakthrough.
• Probenecid: can increase meropenem plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• Aminoglycosides: additive nephrotoxicity; monitor renal function.
• Loop diuretics: may enhance ototoxic potential when combined with other ototoxic agents.
• Anticoagulants (warfarin): possible alteration of INR; check coagulation parameters.